

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

Annual Benefit Report of Beta Bionics, Inc. 2019

Beta Bionics, Inc. (the “Company” or “Corporation”) was incorporated as a Massachusetts benefit corporation on October 21, 2015. This Annual Benefit Report is prepared in accordance with Chapter 156E of the Massachusetts General Laws, Section 15 and covers the Company’s activities through December 31, 2019.

Our General and Specific Public Benefit and Mission

The Company has the stated purpose of creating a general public benefit as well as a specific public benefit of improving public health. To that end, the Company’s Board of Directors adopted and approved comprehensive bylaws enumerating and explaining the manner in which the Company will pursue its specific public benefit purpose for the type 1 diabetes (“T1D”) community. The bylaws establish the following four guiding principles of the Company’s public benefit since inception:

1. To provide and to protect the Corporation’s turnkey solutions for safe and effective autonomous glycemic control;
2. To bring the Corporation’s technology to as many people with T1D as possible in an expeditious and responsible manner;
3. To continue to innovate and to offer the latest advances as expeditiously and responsibly as possible; and
4. To act in the best possible interest of the T1D community in connection with fulfilling the Corporation’s functions.

Actions to Accomplish General and Specific Public Benefit

In 2019, Beta Bionics achieved a number of clinical and regulatory milestones on the path toward regulatory approval and commercialization of the iLet® Bionic Pancreas System. The Company received approval of its investigational device exemption (IDE) application from the U.S. Food and Drug Administration (FDA) to deploy a clinical prototype version of the iLet system (Generation 3) for clinical testing in home-use clinical trials testing the iLet system in the bihormonal configuration. More specifically, the bihormonal configuration of the Gen 3 iLet system was deployed at Massachusetts General Hospital in adults using Zealand Pharma’s investigational dasiglucagon. The 2019 home use bihormonal trial was first of its kind in a number of ways, including (1) being the first closed-loop trial to test a glucagon analog with a potential commercial presentation (i.e. prefilled cartridge), (2) initialized with body weight only, and (3) demonstrating superior mean glucose control and time in range when compared with insulin-only control.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

The topline results of foregoing bihormonal clinical trial were released in 2019 and detailed results are expected to be presented during the American Diabetes Association Scientific Sessions in 2020.

Additionally, in 2019 Beta Bionics successfully raised additional investments amounting to \$63 million from institutional investors. This additional investment completed the Series B/B-2 raise totaling slightly more than \$126 million. This marks an important corporate milestone for Beta Bionics and has provided resources to continue development, clinical, regulatory and preparatory commercialization activities for the iLet system.

The above development, clinical, regulatory and business activities position the Company to ultimately seek regulatory approval and, if achieved, commercialize the iLet system. Information related to the iLet system is preliminary and developing. The iLet system is an investigational device that is not yet approved by the FDA or by any other regulatory body in any other country. Regulatory approval of the iLet system is critical to our success and to ensuring that we meet the essence of the Company's public benefit mission.

No Hindrance to Creation of Public Benefit

No circumstances were present in 2019 that materially hindered the Company's creation of its general or specific public benefit, however, access to additional capital and acceleration of development efforts could have conceivably resulted in creation of additional general and specific public benefit had Series B fundraising activities occurred earlier in the calendar year.

Continued Partnership with B Lab as the Company's Third-Party Public Benefit Review Standard

Shortly upon incorporation, the Company selected B Lab (www.bcorporation.net), a non-profit organization that certifies Benefit Corporations via its B Lab Impact Assessment and B Analytics tools to measure and manage positive impact. B Lab is the most widely recognized and rigorous third-party standard for certifying and measuring corporate public benefit and sustainability performance. Beta Bionics undertook the B Lab Impact Assessment in 2016 and became a certified B Corporation in 2017. Under new B Lab policy, certification continues for a period of three years. Beta Bionics began the assessment cycle in 2019 for recertification in 2020.

About B Corporations

Certified B Corporations are leaders of a global movement of people using business as a force for good. They meet the highest standards of overall social and environmental performance, transparency and accountability and aspire to use the power of business to solve social and environmental problems. There are more than 1,700 Certified B Corporations in over 130 industries and 50 countries with 1 unifying goal – to redefine success in business.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

About B Lab

B Lab is a nonprofit organization that serves a global movement of people using business as a force for good. Its vision is that one day all companies compete not only to be the best in the world, but the Best for the World® and as a result society will enjoy a more shared and durable prosperity. B Lab drives this systemic change by:

1. Building a global community of Certified B Corporations who meet the highest standards of verified, overall social and environmental performance, public transparency, and legal accountability;
2. Promoting Mission Alignment using innovative corporate structures like the benefit corporation to align the interests of business with those of society and to help high impact businesses be built to last;
3. Helping tens of thousands of businesses, investors, and institutions Measure What Matters, by using the B Impact Assessment and B Analytics to manage their impact -- and the impact of the businesses with whom they work -- with as much rigor as their profits;
4. Inspiring millions to join the movement through compelling story-telling by B the Change Media.

For more information, visit www.bcorporation.net, www.bimpactassessment.net, www.b-analytics.net and www.benefitcorp.net.

The B Lab Impact Assessment and Three-Year Certification

In the calendar year 2016, the Company completed the B Lab Impact Assessment and audit process, which is scored on a scale of 0-200. Beta Bionics received a final qualifying score of 82 points on the B Lab Impact Assessment, which measures public benefit impact by analyzing five categories of impact. The Company's initial qualifying score is valid through 2019.

- *Corporate Governance*
The B Lab Impact Assessment analyzes five sub-categories affecting corporate governance. B Lab reviews the Company's benefit mission and engagement with the community and world at large; company accountability to the public; business ethics and compliance; corporate transparency internally and externally; and benefit mission pursuit. The Company scored 21.8 points in the category of Corporate Governance.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

- *Workers*
B Lab reviewed the Company's compensation and wage structure to evaluate corporate responsibility and employee well-being; employee benefit structure is evaluated and analyzed for anti-discrimination and uniform offering; employee education and training; management and worker communication; and job flexibility corporate culture. The Company scored 20.8 points in the category of Workers.
- *Community*
B Lab evaluated the sub-categories of job creation; diversity and inclusion; civic engagement and giving within the community; local involvement; and supplier/product control. The Company scored 32.5 points in the category of Community.
- *Environment*
B Lab evaluates all aspects of business operations for environmental impact and pollution mitigation. Sub-categories include analysis of Beta Bionics' physical offices, impact on Company consumption and production of waste. The Company scored 7.1 points in the category of Environment.
- *Customers*
B Lab considers customer satisfaction, impact and ultimate service to the T1D community with the Company's product. Beta Bionics does not yet produce a commercial product so it was unable to receive a score in this category.

Our Public Benefit Director and Public Benefit Officer

From 2015 through present day, the Company's Benefit Director is Jeff Hitchcock, founder of the not-for-profit Children with Diabetes and a father of a now adult daughter with T1D. Edward Raskin serves as the Company's Benefit Officer, has adult onset T1D and is father to a 13-year old son with T1D.

Correspondence relating to this report may be directed to either individual at Beta Bionics, Inc., 14150 Myford Road, Irvine, California 92606.

No Compensation for Board Positions

The Company has not provided compensation to the members of its Board of Directors for services performed in their roles as members of the Board.

The Commonwealth of Massachusetts

William Francis Galvin

Secretary of the Commonwealth

One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

Owners of 5% or More of the Company's Outstanding Shares

The following persons or entities own five percent or more of the outstanding shares of the Company's stock: (1) Edward R. Damiano; (2) Toby Milgrome; (3) Firas El-Khatib; (4) Eventide Gilead Fund; and (5) Eventide Healthcare & Lifesciences Fund.

No Ownership Connection Between B Lab and the Company

B Lab, including its directors, officers, and those holding of 5% of more of the governing interest in B Lab, has no connection with the Company, including the Company's directors, officers, and those holding of 5% of more of the governing interest in the Company.

Powers of the Board Have Not Been Dispensed with or Restricted

The Company has not dispensed nor restricted the discretion of the Board.

Certification of the Company's Benefit Director

I, Jeff Hitchcock, certify that I am the duly elected Benefit Director of Beta Bionics, Inc. At no time have I held, nor do I currently hold, any other positions within the Company. I have not received any compensation for my services as a Benefit Director of Beta Bionics, Inc. I have reviewed the Company's public benefit report and certify as to the accuracy of its contents. The Company has acted in accordance with its general public benefit as well as its specific public benefit purpose in all material respects during the period covered by this report. I further certify that the directors and officers have complied with subsection (a) of Section 10, subsections (a) to (g) of section 11, and subsection (a) of Section 12 of Chapter 156E of the Massachusetts General Laws. In my opinion, the Company's benefit status has and will continue to have a positive impact on its business including creating a positive consumer opinion, increasing return on investment, positively impacting shareholders and its employees as well as the T1D community.

Executed on this 6th day of March 2020,


JEFF HITCHCOCK